The Evaluation of Oral Acitretin in the Treatment of Psoriasis [PDF]

Carcinoma, Basal Cell Basal Cell Nevus Syndrome Hamartoma Syndrome, Multiple Skin Diseases Keratoderma, Palmoplantar Ker

2 downloads 16 Views 93KB Size

Recommend Stories


Combination of Topical Imiquimod and Oral Acitretin in the Treatment of Multiple Large Basal
The best time to plant a tree was 20 years ago. The second best time is now. Chinese Proverb

The burden of psoriasis
If you want to become full, let yourself be empty. Lao Tzu

(Modified Goeckerman Technique)in Treatment of Psoriasis
Learn to light a candle in the darkest moments of someone’s life. Be the light that helps others see; i

Oral Terbinafine in the treatment of fungal infection of nails
Don't fear change. The surprise is the only way to new discoveries. Be playful! Gordana Biernat

Evaluation of retinectomy in the treatment of severe proliferative vitreoretinopathy
Live as if you were to die tomorrow. Learn as if you were to live forever. Mahatma Gandhi

Significance of the S100A4 Protein in Psoriasis
Do not seek to follow in the footsteps of the wise. Seek what they sought. Matsuo Basho

Acitretin
Happiness doesn't result from what we get, but from what we give. Ben Carson

Evaluation of the CAM treatment for amblyopia
What we think, what we become. Buddha

Overcoming the Stigmata of Psoriasis
Love only grows by sharing. You can only have more for yourself by giving it away to others. Brian

The Psoriasis Association of Malta
The wound is the place where the Light enters you. Rumi

Idea Transcript


We updated the design of this site on December 18, 2017. Learn more.

Find Studies About Studies Submit Studies Resources About Site

The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases ClinicalTrials.gov Identifier: NCT00005660 The safety and scientific validity of this study is the responsibility of the

Recruitment Status : Completed

study sponsor and investigators. Listing a study does not mean it has been

First Posted : May 15, 2000

evaluated by the U.S. Federal Government. Read our disclaimer for details.

Last Update Posted : March 4, 2008

Sponsor: National Cancer Institute (NCI) Information provided by: National Institutes of Health Clinical Center (CC)

Study Details

Tabular View

Study Description

No Results Posted

Disclaimer

How to Read a Study Record

Go to

Brief Summary: This is a continuing study which evaluates the long-term safety and efficacy of oral acitretin in an open manner in the treatment of psoriasis, cutaneous disorders of keratinization, multiple basal cell carcinomas and other retinoid responsive diseases. Condition or disease

Basal Cell Carcinoma Keratosis Palmaris et Plantaris Psoriasis

Detailed Description: This is a continuing study which evaluates the long-term safety and efficacy of oral acitretin in an open manner in the treatment of psoriasis, cutaneous disorders of keratinization, multiple basal cell carcinomas and other retinoid responsive diseases.

Study Design

Go to Study Type : Observational

Estimated Enrollment : 130 participants Official Title: The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases Study Start Date : October 1977 Estimated Study Completion Date : November 2001

Resource links provided by the National Library of Medicine Genetics Home Reference related topics: 9q22.3 microdeletion Bart-Pumphrey syndrome Cole disease Gorlin syndrome Vohwinkel syndrome Palmoplantar keratoderma with deafness MedlinePlus related topics: Psoriasis Skin Conditions Drug Information available for: Acitretin Genetic and Rare Diseases Information Center resources: Tylosis Nevoid Basal Cell Carcinoma Syndrome Darier Disease Basal Cell Carcinoma, Multiple Palmoplantar Keratoderma U.S. FDA Resources

Groups and Cohorts

Go to

Outcome Measures

Go to

Eligibility Criteria

Go to

Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study: Child, Adult, Senior Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria

Patients with widespread involvement (e.g. psoriasis patients with 10 percent or more of body surface area involved) or with severe, recalcitrant localized involvement with a cutaneous disorder (e.g. keratoderma palmaris et plantaris). Patients (and parents of patients who are less than 18 years old) must be advised of presently available alternative forms of therapy. Patient must be available for and agreeable to regular follow up examinations in the clinic for clinical evaluation, blood tests, diagnostic x-rays and possibly skin biopsies. The patient (and parent, guardian, or surrogate where appropriate) must give written informed consent after protocol, including its limitations and risks, are thoroughly discussed with the patients (and parents). Patients who have multiple skin cancers because of xeroderma pigmentosum (XP). No patients with persistently abnormal (SGOT or SGPT greater than 3 times the upper limit of normal) liver function tests. No patients with persistent pre-treatment hypertriglyceridemia (greater than 300 mg/dl). No patients with persistently abnormal (creatinine greater than 3 times the upper limit of normal) renal function tests. No patients with presence of a significant neurological, musculoskeletal or other internal medical disorder which may be aggravated by the addition of retinoid therapy. Patient must not be pregnant or anticipate such an event. Because of the long-term storage of etretinate, a known teratogen, fertile women who may be treated in this protocol, must have skin disease that is severe and recalcitrant to all other standard modalities. These women must also use an effective form of contraception (oral contraceptives or an intrauterine device) while on treatment and at least for 3 years post treatment. No patients with chronic intake of excessive dietary vitamin A (more than 25,000 iu/day).

Contacts and Locations

Go to

Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005660

Locations United States, Maryland

National Cancer Institute (NCI) Bethesda, Maryland, United States, 20892 Sponsors and Collaborators

National Cancer Institute (NCI)

More Information

Go to

ClinicalTrials.gov Identifier: NCT00005660 History of Changes Obsolete Identifiers:

NCT00020956

Other Study ID Numbers:

770172 77-C-0172

First Posted:

May 15, 2000 Key Record Dates

Last Update Posted:

March 4, 2008

Last Verified:

November 2001

Keywords provided by National Institutes of Health Clinical Center (CC): Hypertriglyceridemia

Skin

Teratogenicity

Psoriasis

Ichthyosis

Basal cell carcinoma

Darier's Disease

Skin Cancer

Retinoids Additional relevant MeSH terms: Carcinoma

Jaw Cysts

Psoriasis

Bone Cysts

Keratosis

Cysts

Carcinoma, Basal Cell

Neoplastic Syndromes, Hereditary

Basal Cell Nevus Syndrome

Bone Diseases, Developmental

Hamartoma Syndrome, Multiple

Bone Diseases

Skin Diseases

Musculoskeletal Diseases

Keratoderma, Palmoplantar

Jaw Diseases

Keratoderma, Palmoplantar, Diffuse

Stomatognathic Diseases

Neoplasms, Glandular and Epithelial

Abnormalities, Multiple

Neoplasms by Histologic Type

Congenital Abnormalities

Neoplasms

Genetic Diseases, Inborn

Skin Diseases, Papulosquamous

Hamartoma

Neoplasms, Basal Cell

Neoplasms, Multiple Primary

Odontogenic Cysts

Skin Diseases, Genetic

Smile Life

When life gives you a hundred reasons to cry, show life that you have a thousand reasons to smile

Get in touch

© Copyright 2015 - 2024 PDFFOX.COM - All rights reserved.